Zacks: Atossa Genetics Inc (ATOS) Given Average Rating of “Strong Buy” by Analysts

Atossa Genetics Inc (NASDAQ:ATOS) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price target of $10.00 for the company and are forecasting that the company will post ($0.74) earnings per share for the current quarter, according to Zacks. Zacks has also given Atossa Genetics an industry rank of 101 out of 255 based on the ratings given to related companies.

ATOS has been the topic of a number of recent research reports. ValuEngine upgraded shares of Atossa Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Noble Financial set a $10.00 target price on shares of Atossa Genetics and gave the stock a “buy” rating in a research note on Tuesday, May 15th. Finally, Maxim Group set a $10.00 price target on Atossa Genetics and gave the company a “buy” rating in a report on Thursday, May 3rd.

NASDAQ:ATOS traded down $0.09 on Friday, reaching $2.51. 161,148 shares of the company’s stock were exchanged, compared to its average volume of 393,423. Atossa Genetics has a 52-week low of $2.51 and a 52-week high of $19.08.

Atossa Genetics (NASDAQ:ATOS) last released its earnings results on Monday, May 14th. The company reported ($0.71) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.15. analysts anticipate that Atossa Genetics will post -3.69 EPS for the current fiscal year.

Atossa Genetics Company Profile

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Get a free copy of the Zacks research report on Atossa Genetics (ATOS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.

Leave a Reply